BRIEF—New chief executive at Sernova

Canada’s Sernova has appointed a new chief executive, Cynthia Pussinen, replacing Philip Toleikis, who will take over as chief technology officer.

Formerly focused on research, Sernova is changing strategy to become a full-spectrum developer of cell therapies, with the goal of commercializing a novel Type 1 diabetes product.

Most recently chief technical officer at Spark Therapeutics, Ms Pussinen has also held leadership roles at Ipsen and has extensive experience in the development, licensure and commercialization of biotech products.

Commenting on her appointment, she said: “Sernova has developed novel technology, and I am very excited by the positive preclinical and clinical results thus far.”

She added: “The company is a pioneer in creating new ways to address some of the most challenging chronic diseases, providing the possibility of a life-changing ‘functional cure’ for conditions including Type 1 diabetes.”